



SmartPA Criteria Proposal

| | |
|-----------------------------------|--|
| Drug/Drug Class: | Antifungals, Topical PDL Edit |
| First Implementation Date: | July 10, 2014 |
| Proposed Date: | September 9, 2023 |
| Prepared For: | MO HealthNet |
| Prepared By: | MO HealthNet/Conduent |
| Criteria Status: | <input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria |

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Many types of fungal germs (fungi) live harmlessly in the soil, on food, on our skin, and in other places in the environment. However, some types of fungi can thrive and multiply on the surface of the body causing infection of the skin, nails, mouth, or vagina. The most common fungi to cause skin infections are the tinea group of fungi. For example, tinea pedis (athlete's foot) is a common fungal infection of the toes and feet. Thrush is a common fungal infection of the mouth and vagina caused by an overgrowth of candida which is a yeast (a type of fungus). Small numbers of candida commonly live on the skin. However, certain conditions can cause candida to multiply and cause infection. Topical antifungals are used to treat these quite common infections.

Total program savings for the PDL classes will be regularly reviewed.

| Program-Specific Information: | Preferred Agents | Non-Preferred Agents |
|-------------------------------|--|--|
| | <ul style="list-style-type: none"> Alevazol[®] OTC Butenafine Crm OTC Ciclopirox 0.77% Crm/Susp Clotrimazole Crm OTC Clotrimazole Soln Rx Clotrimazole/Betamethasone Crm Ketoconazole Shampoo Miconazole Crm/Pwd/Spray Pwd OTC Nyamy[®] Pwd Nystatin Crm/Oint/Pwd Nystop[®] Pwd Terbinafine Crm OTC Tolnaftate Crm/Pwd OTC | <ul style="list-style-type: none"> Azolen[™] Tinc OTC CicloDan[®] Ciclopirox 0.77% Gel Ciclopirox 1% Shampoo Ciclopirox 8% Kit/Soln Clotrimazole Crm Rx Clotrimazole Soln OTC Clotrimazole/Betamethasone Lot Econazole Ertaczo[®] Extina[®] Fungoid[®]-D Jublia[®] Kerydin[®] Ketoconazole Crm/Foam Ketodan[®] Loprox[®] Lotrimin[®] |

| | |
|--|---|
| | <ul style="list-style-type: none"> • Luliconazole • Luzu® • Mentax® • Miconazole-Zinc-Petro 0.25-15% • Naftifine • Naftin® • Nizoral® A-D • Nystatin/Triamcinolone • Oxiconazole • Oxistat® • Tavaborole • Tinactin® • Vusion® |
|--|---|

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Clinical Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Antifungal Agents, Topical
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 4 or more preferred agents
 - Documented trial period of preferred agents **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
 Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: “DERMATOLOGIC AGENTS: Topical Anti-fungals”, Gainwell Technologies; Last updated February 27, 2023.
- Evidence-Based Medicine Analysis: “Topical Antifungal Agents”, UMKC-DIC; Last updated January 2023.
- USPDI, Micromedex; 2023.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.